A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 22, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions

Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive

Interventions

DRUG

gilteritinib

Oral

Trial Locations (2)

RECRUITING

Virginia Cancer Specialists PC, Fairfax

RECRUITING

Hackensack University Medical Center, Hackensack

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY